The Federal Circuit’s March 19, 2008, decision in Amgen Inc. v. International Trade Commission, No: 2007-1014 (Fed. Cir. 2008), significantly expanded both the ITC’s jurisdiction to conduct investigations and the defenses available to some accused infringers.
This decision, by a split panel, will have important effects on the frequency and scope of Section 337 investigations of alleged patent infringement involving FDA-regulated products.
Read the complete article by clicking on the link below.
Reprinted with permission from Portfolio Media, Inc.
Related Insights
July 23, 2025
Events
Healthcare Supply Chain Compliance Challenges: Vendor Management, Contract Negotiation, Tariff Impact
Foley partner Monica Chmielewski, vice chair of the firm’s Health Care Practice Group, is speaking in Strafford’s upcoming webinar titled “Healthcare Supply Chain Compliance Challenges: Vendor Management, Contract Negotiation, Tariff Impact” on July 23.
September 30, 2025
Events
FDA Regulation of AI-Enabled Medical Devices
Foley partner Kyle Faget, co-chair of the firm’s Medical Devices Area of Focus, is speaking at the American Bar Association Health Law Section’s Healthcare Delivery & Innovation Conference on September 30.
July 10, 2025
Foley Viewpoints
One Big Beautiful Bill Act Permanently Increases the Lifetime Estate, Gift and GST Tax Exclusion
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (OBBBA). The OBBBA extended and may permanent many key…